Moderna falls after co withdraws application for COVID-flu combination vaccine

Shares of vaccine maker Moderna MRNA.O fall 1.4% to $27.60 premarket

Co says it is voluntarily withdrawing its marketing application for its COVID-flu combination vaccine for adults aged 50 years and older

Co plans to resubmit its application later this year, after late-stage efficacy data of its experimental seasonal influenza vaccine, mRNA-1010, is available

The company's decision comes a day after the U.S. Food and Drug Administration said it would require new clinical trials for approval of annual COVID-19 boosters for healthy people under 65 years

"Moderna continues to expect interim data from the mRNA-1010 trial to be available this summer", co says

Up to last close, stock down 32.7% YTD